Study Purpose: This research is about using a medicine called sacituzumab govitecan (SG) to treat advanced triple-negative breast cancer (TNBC), focusing on different doses and schedules.
Treatment Details: The study is in two phases. Phase 1 checks safety and how the body handles the drug, while Phase 2 checks more deeply into safety and effectiveness. Participants must be 18 or older, with confirmed TNBC.
Key Points to Consider:
- Duration: This study has two phases, each with different requirements.
- Eligibility: Must have certain genetic and health conditions and not have had specific previous treatments.
- Risks/Benefits: The study will look at safety and how well the treatment works, with potential benefits and some risks.
Certain medical tests like CT or MRI will measure the disease, and participants must have good health scores and organ function. People who had specific prior treatments are not eligible.
How understandable was the trial content above?
Hard to understand
Easy to understand